A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer by Marcuello, E et al.
A genotype-directed phase I–IV dose-finding study of irinotecan
in combination with fluorouracil/leucovorin as first-line treatment
in advanced colorectal cancer
E Marcuello
1,4,DP a ´ez
1,4, L Pare ´
2, J Salazar
2,3, A Sebio
1, E del Rio
2 and M Baiget*,2
1Medical Oncology, Universitat Auto `noma de Barcelona, Pare Claret 167, Barcelona 08025, Spain;
2Genetics Departments, Hospital de la Santa
Creu i Sant Pau, Universitat Auto `noma de Barcelona, Pare Claret 167, Barcelona 08025, Spain;
3U-705 CIBERER, Barcelona, Spain
BACKGROUND: Infusional fluorouracil/leucovorin (FU/LV) plus irinotecan (FOLFIRI) is one of the standard first-line options for patients
with metastatic colorectal cancer (mCRC). Irinotecan is converted into 7-ethyl-10-hydroxycamptothecin (SN-38) by a
carboxylsterase and metabolised through uridine diphosphate glucuronosyl transferase (UGT1A1). The UGT1A1*28 allele has
been associated with the risk of developing severe toxicities. The present trial was designed to define the maximum tolerated dose
according to UGT1A1 genotype. This report focuses on the results of tolerance to different escalated doses of FOLFIRI first-line of
chemotherapy.
PATIENTS AND METHODS: Patients undergoing first-line treatment for mCRC and eligible for treatment with FOLFIRI were classified
according to UGT1A1 genotype. A total of 94 patients were eligible for dose escalation of irinotecan. The starting dose of biweekly
irinotecan was 180mgm
 2 for the *1/*1, 110mgm
 2 for the *1/*28 and 90mgm
 2 for the *28/*28 genotypes.
RESULTS: The dose of irinotecan was escalated to 450mgm
 2 in patients with the *1/*1 genotype, to 390mgm
 2 in those with the
*1/*28 genotype and to 150mgm
 2 in those with the *28/*28 genotype. Neutropenia and diarrhoea were the most common grade
3 or 4 toxicities.
CONCLUSIONS: Our results demonstrated that the recommended dose of 180mgm
 2 for irinotecan in FOLFIRI is considerably lower
than the dose that can be tolerated for patients with the UGT1A1 *1/*1 and *1/*28 genotypes. The maximum tolerable dose
(MTD) in patients with a high-risk UGT1A1 *28/*28 genotype is 30% lower than the standard dose of 180mgm
 2.
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Colorectal carcinoma is the third cause of cancer-related mortality
in industrialised countries. Although some metastatic disease may
benefit from surgical resection, chemotherapy is the prime
therapeutic tool in advanced disease, as it aims to palliate
symptoms and increase time to disease progression (TTP) as well
as overall survival.
In the last 40 years, fluorouracil (FU) has been the most widely
used chemotherapeutic agent in the treatment of advanced disease.
In the early 1980s, a modulation of FU with folinic acid helped to
increase the response rate and lengthen the TTP. Furthermore, the
advent of new drugs such as irinotecan and oxaliplatin in different
combinations with fluoropyrimidines has improved outcome in
many patients (Douillard et al, 2000; Saltz et al, 2000; Ko ¨hne et al,
2005; Saunders and Iveson, 2006). This scenario has improved
even more with the recent introduction of new biological drugs
such as bevacizumab or cetuximab in the treatment schemes
(Hurwitz et al, 2004; Van Cutsem et al, 2009).
Infusional FU/leucovorin (LV) plus irinotecan (FOLFIRI) is one
of the standard first-line options for patients with metastatic
colorectal cancer (mCRC). The recommended dose for irinotecan
in combination with FU in first-line chemotherapy is 180mgm
 2
every 2 weeks (Ducreux et al, 1999; Tournigand et al, 2004), and a
phase-II trial reported a high response rate using 260mgm
 2 every
2 weeks with a median TTP of 8 to 10 months and median survival
of 22 months (Duffour et al, 2002). When doses of irinotecan were
increased, the most frequent side effects were myelotoxicity and
diarrhoea.
Irinotecan is converted into 7-ethyl-10-hydroxycamptothecin
(SN-38) by a carboxylsterase, and finally metabolised through
uridine diphosphate glucuronosyl transferase enzyme (UGT),
predominantly by UGT1A1 isoenzyme. UGT1A1 is a polymorphic
enzyme. The number of TA repeats (5, 6, 7 or 8) in the TATA
box of the UGT1A1 promoter region is inversely correlated
with the gene transcription efficiency and overall enzyme activity.
The presence of seven repeats (TA7) results in the variant
allele UGT1A1*28 compared with the normal genotype of six TA
repeats (UGT1A1*1). This polymorphism has been related to
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smyelosuppression and severe diarrhoeic toxicity in UGT1A1*28/
*28 and UGT1A1*1/*28 genotypes (Ando et al, 2000; Innocenti
et al, 2004; Marcuello et al, 2004; Rouits et al, 2004; Toffoli et al,
2006; Hoskins et al, 2007; Kim and Innocenti, 2007). Individualis-
ing doses according to UGT1A1 genotype has been proposed to
optimise treatment efficacy and tolerance. The present trial was
designed to define the maximum tolerated dose (MTD) according
to UGT1A1 genotype. We report the results of tolerance to
different escalated doses of irinotecan plus infusional 5-fluorour-
acil/leucovorin (FOLFIRI) in first-line chemotherapy.
PATIENTS AND METHODS
Patients
A total of 94 patients receiving the FOLFIRI regimen were included
in the study. Eligibility criteria included histologically proven
mCRC or a locally advanced recurrence after surgery, age X18
years, an Eastern cooperative oncology group (ECOG) perfor-
mance status of 0 to 2, life expectancy of more than 3 months and
adequate bone marrow function (haemoglobin X10gdl
 1, neu-
trophil count X1500ml
 1 and platelet count X100000ml
 1), renal
function (creatinine clearance more than 60mlmin
 1) and liver
function (serum creatinine and bilirubin o1.5 the upper limit of
normal and AST and ALT p2.5 the upper limit of normal). The
exclusion criteria were ECOG42, apparent jaundice or severe
comorbidities. Analysis of the UGT1A1 genotype was mandatory
for inclusion in this trial.
Before starting the treatment, complete medical history, physical
examination, complete analytical studies including blood counts,
liver and renal function, ionogram, lactate dehydrogenase, alkaline
phosphatise, CEA determination and chest, abdomen and pelvic
computed tomography scan were performed in all patients.
Patients were classified according to the European Organisation
for Research and Treatment of Cancer (EORTC) clinical model
validated by Ko ¨hne et al (2002). Follow-up was conducted
throughout the treatment period until disease progression or
death. Responses and progression were evaluated every 12 weeks
using Response Evaluation Criteria in Solid Tumours (RECIST).
Time to disease progression was assessed from inclusion until
disease progression was evident. Toxicity was assessed at every
visit using the National Cancer Institute Common Toxicity Criteria
version 3.0. Written informed consent was obtained and the study
was approved by the Institutional Ethics Committee and by the
Spanish Agency for Medicines and Medical Devices (N1 EudraCT
‘2007-006788-65’).
Study design and dose escalation
The primary end-point was assessment of the MTD of irinotecan
and dose-limiting toxicity (DLT) at cycle 1. Secondary end-points
included the objective response rate and TTP.
Patients were treated with the FOLFIRI scheme. The dose of
irinotecan, administered as a 2-h intravenous (i.v.) infusion on day
1, was escalated at different levels according to UGT1A1 genotype.
The starting dose of irinotecan was 180 in *1/*1 patients; 110 in
*1/*28 and 90 in *28/*28.
Leucovorin was administered as a 200mgm
 2 in 2h of i.v.
infusion during irinotecan infusion followed by 5-FU at
400mgm
 2 bolus injection, and 5-FU 600mgm
 2 in 22h infusion
on days 1 and 2 (Douillard et al, 2000). Treatment was repeated
every 14 days, if blood counts were adequate. One cycle of
treatment consisted of two courses of chemotherapy in 28 days. A
complete analytical study was carried out every 7 days during the
first cycle.
Dose-limiting toxicity was defined when haematologic grade 4
toxicity, or non-haematologic grade 3–4 toxicities appeared
during cycle 1 and persisted despite supportive measures
(including antiemetics or antidiarrhoeal agents). Any kind of
toxicity that caused hospitalisation or a delay of more than 2 weeks
in the treatment administration was considered a DLT. Three
patients were scheduled at each dose level. If no toxicity was
detected, three new patients were treated with the following dose
level. When one patient presented DLT, three new patients
received that dose level, and if only one patient had DLT, the
following patients were treated with the higher dose level. If two
out of three or two out of six patients experienced DLT, the level
below was considered MTD. Patients with DLT continued with a
20% dose reduction in the following cycles. Colony-stimulating
granulocyte factor (FEC-G) was allowed in patients with grade 3–4
neutropenia.
UGT1A1 genotyping assay
Genomic DNA was extracted from peripheral leukocytes by the
salting-out procedure (Miller et al, 1989). The TA index of the
UGT1A1 promoter was genotyped by fragment sizing. Polymerase
chain reaction was performed in a total volume of 25ml containing
template DNA (80ngml
 1), according to Monaghan et al (1996).
The primers used were a forward primer that was modified by
the addition of a 50 fluorescent-labelled FAM and an unlabelled
reverse primer (UGT-FAM_F; 50-GTCACGTGACACAGTCAAA
C-30, UGT_R 50-TTTGCTCCTGCCAGAGGTT-30). The PCR
product (TA*1, 98bp; TA*28, 100bp), the internal size standard
and Hi-Di formamide (GeneScan 500, Applied Biosystems, Foster
City, CA, USA) were mixed. The samples were then run in the ABI
Prism 3100 Genetic Analyzer (Applied Biosystems). Fragment sizes
were determined by comparison with the internal standard
GeneScan 500 using the local Southern algorithm and analysed
by GeneMapper software version 3.5 (Applied Biosystems).
Normal, heterozygous and homozygous sequenced samples were
included on every run as a quality control. Genotypes were
assigned based on the number of TA repeats in each allele (i.e.,
TA*1/*1, TA*1/TA*28 and TA*28/TA*28).
Statistics
Differences between categorical variables were measured by the
w
2-test. The Mann–Whitney test was used for comparisons
between responses in UGT1A1 genotype and dose. To ascertain
the effect of irinotecan dose and the UGT1A1 genotype on
response rate, a logistic regression was used as a multivariate
method after adjustment for other relevant clinical variables. Time
to disease progression was assessed by the Kaplan–Meier method
and log-rank test for comparisons. Results were considered
statistically significant when P-values were less than 0.05.
RESULTS
Patient characteristics
From July 2005 to December 2010, 94 white mCRC or patients with
a locally advanced recurrence after surgery were included. Median
age at the time of diagnosis was 63 years old. Their characteristics
and UGT1A1 genotypes are shown in Table 1.
Dose escalation, toxicities and DLT
The dose of irinotecan was escalated from 180 to 450mgm
 2 in
*1/*1 patients; from 110 to 390mgm
 2 in *1/*28 and from 90 to
150mgm
 2 in *28/*28 (Table 2).
Table 3 summarises the total number of patients included at
each dose level of irinotecan together with the number of cases
with DLT.
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sIn the group with the *1/*1 genotype after two patients
presented DLT (grade 3 diarrhoea at 220mgm
 2 and grade 3
asthenia at 260mgm
 2), six additional patients were treated with
260mgm
 2 and no DLT was observed. No patient presented a DLT
in the 300mgm
 2 level. In the next level of doses (340mgm
 2),
one out of six patients developed a DLT (grade 4 asthenia and
grade 3 urinary tract infection plus fever causing hospitalisation).
One out of six had a DLT (prolonged grade 4 asthenia and grade 3
neutropenia) at 390mgm
 2. One further patient at 390mgm
 2
level treated with only one dose of irinotecan was withdrawn
because of a protocol violation. Finally, two out of five patients
presented a DLT at 450mgm
 2. One patient presented grade 3
diarrhoea and vomiting plus a secondary grade 4 asthenia causing
severe dehydration requiring intravenous fluids and hospitalisa-
tion. The other case of DLT at 450mgm
 2 consisted of grade 3
diarrhoea and asthenia. Therefore, the MTD in the group of
patients with a *1/*1 genotype was 390mgm
 2 (Table 3).
In the group with a *1/*28 genotype no DLT was observed in the
patients treated with less than 300mgm
 2. One patient presented a
grade 4 neutropenia at 300mgm
 2 and one patient presented a
grade 3 diarrhoea and asthenia at 340mgm
 2 level with catheter-
related sepsis by Staphylococcus aureus requiring intravenous
antibiotics and hospitalisation. This dose was the MTD in the
*1/*28 genotype patients because the two first patients treated with
a dose of 390mgm
 2 experienced a DLT (grade 3 asthenia and
persistent grade 3 neutropenia, respectively) (Table 3).
In the *28/*28 genotype only one of six patients presented a DLT
(grade 3 diarrhoea) at 90mgm
 2. No patient presented a DLT at
the 130mgm
 2 level. As two of five patients at 150mgm
 2
developed a DLT, the MTD was established at 130mgm
 2. One
patient presented grade 4 neutropenia and grade 3 asthenia and
the other presented grade 3 asthenia and grade 3 constipation with
intestinal subocclusion (Table 3).
Among all grade 3–4 toxicities, the most frequent severe
haematological toxicity during cycle 1 was grade 3–4 neutropenia
Table 1 Patients characteristics
















No of metastatic sites
16 3 6 7








Abbreviation: ECOG¼Eastern cooperative oncology group.










Level 1 180 110 90
Level 2 220 125 130
Level 3 260 150 150
Level 4 300 180
Level 5 340 220
Level 6 390 260
Level 7 450 300
Level 8 340
Level 9 390






















with DLT Type of DLT
90 — — — — — — 6 1 Grade 3 diarrhoea
110 — — — 3 0 — — — —
125-130 — — — 3 0 — 3 0 Grade 3 asthenia
150 — — — 3 0 — 5 2 Grade 4 neutropenia.
Grade 3 asthenia and
constipation
180 3 0 — 9
a 0— — — —
220 6 1 Grade 3 diarrhoea and nausea 3 0 — — — —
260 12
a 1 Grade 3 asthenia 3 0 — — — —
300 3 0 6 1 Grade 4 neutropenia — — —
340 6 1 Grade 4 asthenia. Urinary
tract infection
6 1 Grade 3 diarrhoea. Sepsis
by Staph aureus
—— —
390 6 1 Grade 4 asthenia 2 2 Grade 3 neutropenia
Grade 3 asthenia
—— —
450 5 2 Grade 3 diarrhoea, vomiting
and grade 4 asthenia.
Grade 3 diarrhoea and asthenia
—— — —— —
Abbreviation: DLT¼dose-limiting toxicity.
aSix additional patients.
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s(25%). Grade 3–4 asthenia was the most common non-haemato-
logical toxicity (18%). Others severe toxicities were grade 3
diarrhoea (10%), infection without neutropenia (4%), nausea/
vomiting (4%) and mucositis (1%). The different grade 3 to 4
toxicities according to the UGT1A1 genotype (including DLT and
non-DLT) are summarised in Table 4.
Effect of irinotecan dose on tumour response and survival
In all, 56 patients were assessable for tumour response. The overall
response rate (ORR¼complete plus partial response) was 46%
(n¼25). The ORR was 60% in patients with *1/*1 genotype, 39%
in those with *1/*28 genotype and 13% in *28/*28 (P¼0.049).
To evaluate the relation between irinotecan dose and response
rate, we grouped patients into two cohorts according to the median
dose of irinotecan: 27 patients treated with X260mgm
 2 and 29
patients treated with a o260mgm
 2. A statistically significant
relationship between irinotecan dose and response rate was
observed (U-test, Mann–Whitney; P¼0.023). In all, 67% of
patients treated with X260mgm
 2 of irinotecan achieved a
complete or partial response in comparison with only 24% of
patients treated with o260mgm
 2 (P¼0.001) (Table 5). In the
logistic regression analysis only a X260mgm
 2 irinotecan dose
independently predicted the probability of response to FOLFIRI
(odds ratio (OR)¼5.71; CI 95%: 1.76–18.51, P¼0.004). The dose
level was also associated with a better response rate in the logistic
regression analysis (P¼0.02).
Median follow-up time was 13 months (range, 1–57 months).
Median TTP was 10 months (range, 8–12 months). There were no
differences in TTP according to the genotype (P¼0.58). Median
TTP was higher in patients treated with X260mgm
 2 of
irinotecan (16 months) than in patients treated with o260mgm
 2
of irinotecan (7 months) months (P¼0.003).
In patients with assessable tumour response, a higher TTP was
observed in those who achieved a complete or partial response
(11 months) than in those with stable disease (10 months) or
progressive disease (2.7 months; Po0.001) after FOLFIRI treat-
ment. The Cox regression model included the UGT1A1 genotype,
ECOG, sex, age, clinical-risk EORTC classification and primary
tumour localisation. The risk-group classification (P¼0.003;
HR¼1.95; CI 95%: 1.25–3.01) and a X260mgm
 2 irinotecan
dose (P¼0.003; HR¼2.9; CI 95%: 1.43–5.88) were independent
predictors of TTP after adjustment for the other clinically relevant
variables.
DISCUSSION
This study evaluated the DLT and MTD of irinotecan in the
FOLFIRI regimen in first-line chemotherapy in mCRC according to
UGT1A1 genotype. In this dose-escalating trial, we establish that
the standard dose of 180mgm
 2 for irinotecan is significantly
lower than the dose that can be tolerated by patients with a
UGT1A1 *1/*1 or *1/*28 genotype. A dose escalation was evaluated
for the first time in patients with a high-risk UGT1A1 *28/*28
genotype, and we demonstrated that the MTD was 30% lower than
the standard dose of 180mgm
 2. Although results of tumour
response are exploratory, with this dose (130mgm
 2), irinotecan
was poorly effective and a more active chemotherapeutic regimen
should be considered for this group of patients.
This dose escalation trial of irinotecan in patients with UGT1A1
*1/*1 and *1/*28 genotypes led us to establish that 390 and
340mgm
 2, respectively, can be safely administered every 2 weeks
(MTD) in mCRC patients undergoing first-line treatment with the
FOLFIRI regimen. Though slightly higher, these doses, are very
similar to those reported in a recent phase I study of irinotecan
administered in the FOLFIRI regimen in Italian patients with
mCRC: 370mgm
 2 for patients with UGT1A1 *1/*1 genotype, and
310mgm
 2 for those with a *1/*28 genotype. These authors
identified these doses as safe to administer when mCRC patients
were stratified according to the UGT1A1 genotype, and patients
genetically at risk for toxicity (*28/*28) were excluded (Toffoli
et al, 2010). One limitation of our study compared with this work
is that a pharmacokinetics analysis was not carried out to describe
the effect of different irinotecan doses on patient’s drug exposure.
In Japan, the health authorities have approved a two-weekly
dose of 150mgm
 2 for irinotecan monotherapy. A phase I/II study
determined the recommended dose of FOLFIRI for patients with
mCRC without the UGT1A1 *28/*28 genotype. Although the MTD
was not reached, the conclusions favoured an increase in the
irinotecan dose for patients without the *28 allele to 180mgm
 2
(Yamashita et al, 2011). In this same population, a phase I study of
irinotecan and doxifluridine (50-DFUR) for mCRC patients without
UGT1A1 *28/*28 genotype concluded that the recommended doses
of biweekly irinotecan were 150mgm
 2 for patients with the
UGT1A1 *1/*1 genotype and 70mgm
 2 for those with the *1/*28
genotype (Hazama et al, 2010). However, a recent Japanese study
concluded that no significant differences in the efficacy or toxicity
of FOLFIRI between patients with UGT1A1*1/*1 genotype and
those with UGT1A1*1/*6 or *1/*28 genotype, when irinotecan dose
is 180mgm
 2 (Sunakawa et al, 2010). This suggest that when
UGT1A1 *28/*28 genotype is excluded, the dose of irinotecan is
more relevant than the genotype.
In Caucasian populations, in Italy and Spain, the recommended
doses in the phase I studies carried out to date are higher than
those in the Japanese trials. These differences may perhaps be
attributed to the ethnic differences in UGT1A1 genotypes and/or
differences in the therapeutic regimens used. Other combinations
with irinotecan that differ from the standard FOLFIRI regimen,








Toxicity n (%) n (%) n (%)
Diarrhoea 4 (10) 2 (5) 3 (21)
Nausea/vomiting 2 (5) 2 (5) 0 ( )
Asthenia 10 (24) 4 (11) 3 (21)
Mucositis/stomatitis 1 (2) 0 ( )0 (  )
Anorexia 0 ( )0 (  )0 (  )
Infection without concomitant
grade III–IV neutropenia
2 (5) 0 ( ) 1 (7)
Anaemia 0 ( )0 (  )0 (  )
Neutropenia 9 (22) 10 (26) 4 (29)
Thrombocytopenia 0 ( )0 (  )0 (  )
Fever with concomitant neutropenia 0 ( )0 (  )0 (  )
Abbreviation: DLT¼dose-limiting toxicity.
Table 5 Response rate: effect of irinotecan dose and UGTA1 genotype
CR+PR SD+PD
Response nn Percentage CR PR n %S DP D P
Overall 56 25 46 4 21 31 54 22 9
*1/*1 25 15 60 1 14 10 40 7 3 0.049
*1/*28 23 9 39 3 6 14 61 8 4
*28/*28 8 1 13 – 1 7 87 5 2
X260mgm
 2 27 18 67 2 16 9 33 8 1 0.001
o260mgm
 2 29 7 24 2 5 22 76 14 8
Abbreviations: CR¼complete response; PD¼progressive disease; PR¼partial
response; SD¼stable disease.
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sinclude those using biological agents, should be explored before
making any conclusions.
Our present results also show that a dose X260mgm
 2 is an
independent predictor of a better response and higher TTP in
mCRC patients without the risk genotype (*28/*28). We therefore
suggest that in future phase II and phase III studies, the initial dose
of irinotecan in FOLFIRI regimen should be at least 260mgm
 2 in
Caucasian patients who have either the *1/*1 or *1/*28 UGT1A1
genotype.
Finally, we suggest that as the MTD in patients with a high-risk
UGT1A1 *28/*28 genotype (130mgm
 2) is ineffective, other more
active chemotherapeutic regimen should be considered for these
patients.
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